Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00237172|
Recruitment Status : Completed
First Posted : October 12, 2005
Last Update Posted : May 1, 2012
|Condition or disease||Intervention/treatment||Phase|
|Gastrointestinal Stromal Tumors||Drug: Imatinib Mesylate||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)|
|Study Start Date :||September 2002|
|Actual Primary Completion Date :||July 2005|
Experimental: Imatinib Mesylate
400 mg once daily
Drug: Imatinib Mesylate
Other Name: STI571
- To study the antineoplastic effect of the investigational drug.
- To study the safety and pharmacokinetics of the investigational drug.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00237172
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|